These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 33839159)

  • 1. Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET.
    Neijssen J; Cardoso RMF; Chevalier KM; Wiegman L; Valerius T; Anderson GM; Moores SL; Schuurman J; Parren PWHI; Strohl WR; Chiu ML
    J Biol Chem; 2021; 296():100641. PubMed ID: 33839159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of
    Yun J; Lee SH; Kim SY; Jeong SY; Kim JH; Pyo KH; Park CW; Heo SG; Yun MR; Lim S; Lim SM; Hong MH; Kim HR; Thayu M; Curtin JC; Knoblauch RE; Lorenzi MV; Roshak A; Cho BC
    Cancer Discov; 2020 Aug; 10(8):1194-1209. PubMed ID: 32414908
    [No Abstract]   [Full Text] [Related]  

  • 3. Fc-mediated activity of EGFR x c-Met bispecific antibody JNJ-61186372 enhanced killing of lung cancer cells.
    Grugan KD; Dorn K; Jarantow SW; Bushey BS; Pardinas JR; Laquerre S; Moores SL; Chiu ML
    MAbs; 2017 Jan; 9(1):114-126. PubMed ID: 27786612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amivantamab: a monoclonal EGFR-MET bispecific antibody for EGFR exon 20 insertion in non-small cell lung cancer.
    Xie Y; Lu Q; Wang JQ; Bo L; Ashby CR; Chen ZS
    Drugs Today (Barc); 2022 Aug; 58(8):389-398. PubMed ID: 35983925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor-Resistant Lung Tumors.
    Moores SL; Chiu ML; Bushey BS; Chevalier K; Luistro L; Dorn K; Brezski RJ; Haytko P; Kelly T; Wu SJ; Martin PL; Neijssen J; Parren PW; Schuurman J; Attar RM; Laquerre S; Lorenzi MV; Anderson GM
    Cancer Res; 2016 Jul; 76(13):3942-53. PubMed ID: 27216193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel bispecific c-MET/CTLA-4 antibody targetting lung cancer stem cell-like cells with therapeutic potential in human non-small-cell lung cancer.
    Li JF; Niu YY; Xing YL; Liu F
    Biosci Rep; 2019 May; 39(5):. PubMed ID: 29187584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Cell-surface Antigen Expression on Target Engagement and Function of an Epidermal Growth Factor Receptor × c-MET Bispecific Antibody.
    Jarantow SW; Bushey BS; Pardinas JR; Boakye K; Lacy ER; Sanders R; Sepulveda MA; Moores SL; Chiu ML
    J Biol Chem; 2015 Oct; 290(41):24689-704. PubMed ID: 26260789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Analysis of the Effcacy and Safety of Amivantamab in Non-small Cell Lung Cancer 
Patients with EGFR/MET Gene Abnormalities: A Single Center's Experience].
    Wang J; Chi Y; Chen H; Jia B; Zhai X; Ma M; Li J; Zhuo M
    Zhongguo Fei Ai Za Zhi; 2022 Jul; 25(7):493-500. PubMed ID: 35899447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amivantamab: First Approval.
    Syed YY
    Drugs; 2021 Jul; 81(11):1349-1353. PubMed ID: 34292533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel bispecific EGFR/Met antibody blocks tumor-promoting phenotypic effects induced by resistance to EGFR inhibition and has potent antitumor activity.
    Castoldi R; Ecker V; Wiehle L; Majety M; Busl-Schuller R; Asmussen M; Nopora A; Jucknischke U; Osl F; Kobold S; Scheuer W; Venturi M; Klein C; Niederfellner G; Sustmann C
    Oncogene; 2013 Dec; 32(50):5593-601. PubMed ID: 23812422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of [
    Cavaliere A; Sun S; Lee S; Bodner J; Li Z; Huang Y; Moores SL; Marquez-Nostra B
    Eur J Nucl Med Mol Imaging; 2021 Feb; 48(2):383-394. PubMed ID: 32770372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/cMet Bispecific Antibody, Induces Receptor Downmodulation and Antitumor Activity by Monocyte/Macrophage Trogocytosis.
    Vijayaraghavan S; Lipfert L; Chevalier K; Bushey BS; Henley B; Lenhart R; Sendecki J; Beqiri M; Millar HJ; Packman K; Lorenzi MV; Laquerre S; Moores SL
    Mol Cancer Ther; 2020 Oct; 19(10):2044-2056. PubMed ID: 32747419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amivantamab, an Epidermal Growth Factor Receptor (EGFR) and Mesenchymal-epithelial Transition Factor (MET) Bispecific Antibody, Designed to Enable Multiple Mechanisms of Action and Broad Clinical Applications.
    Cho BC; Simi A; Sabari J; Vijayaraghavan S; Moores S; Spira A
    Clin Lung Cancer; 2023 Mar; 24(2):89-97. PubMed ID: 36481319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amivantamab for the treatment of
    Vyse S; Huang PH
    Expert Rev Anticancer Ther; 2022 Jan; 22(1):3-16. PubMed ID: 34913823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of
    Emdal KB; Dittmann A; Reddy RJ; Lescarbeau RS; Moores SL; Laquerre S; White FM
    Mol Cancer Ther; 2017 Nov; 16(11):2572-2585. PubMed ID: 28830985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.
    Nakagawa T; Takeuchi S; Yamada T; Nanjo S; Ishikawa D; Sano T; Kita K; Nakamura T; Matsumoto K; Suda K; Mitsudomi T; Sekido Y; Uenaka T; Yano S
    Mol Cancer Ther; 2012 Oct; 11(10):2149-57. PubMed ID: 22844075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The development of amivantamab for the treatment of non-small cell lung cancer.
    Brazel D; Nagasaka M
    Respir Res; 2023 Oct; 24(1):256. PubMed ID: 37880647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Editorial: Global Regulatory Initiatives Deliver Accelerated Approval of the First Bispecific Therapeutic Monoclonal Antibody for Advanced Non-Small Cell Lung Cancer (NSCLC).
    Parums DV
    Med Sci Monit; 2021 Sep; 27():e934854. PubMed ID: 34565792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel tetravalent bispecific antibody targeting programmed death 1 and tyrosine-protein kinase Met for treatment of gastric cancer.
    Hou W; Yuan Q; Yuan X; Wang Y; Mo W; Wang H; Yu M
    Invest New Drugs; 2019 Oct; 37(5):876-889. PubMed ID: 30511201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combining onartuzumab with erlotinib inhibits growth of non-small cell lung cancer with activating EGFR mutations and HGF overexpression.
    Sano Y; Hashimoto E; Nakatani N; Abe M; Satoh Y; Sakata K; Fujii T; Fujimoto-Ouchi K; Sugimoto M; Nagahashi S; Aoki M; Motegi H; Sasaki E; Yatabe Y
    Mol Cancer Ther; 2015 Feb; 14(2):533-41. PubMed ID: 25522765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.